<DOC>
	<DOCNO>NCT01534455</DOCNO>
	<brief_summary>- Lapatinib combination capecitabine approve treatment woman HER-2-positive advance breast cancer progress anthracycline- , taxane- , trastuzumab-containing therapy . The use combination limit overlap toxicity diarrhea cutaneous side effect . - A significant number patient receive today capecitabine trastuzumab first- second-line treatment . Therefore , combination lapatinib less toxic cytotoxic agent need . - Eribulin mesylate ( E7389 ) synthetic analog Halichondrin B ( HalB ) , large polyether macrolide isolate marine sponge . Eribulin mechanistically unique antagonist microtubule dynamic among tubulin-targeted agent , lead inhibition microtubule growth absence effect microtubule shortening , formation non- productive tubulin aggregate . - Eribulin mesylate dose 1.4 mg/m² give day 1 , 8 every 3 week show well overall survival 2.5 month compare treatment physician choice patient locally advance metastatic breast cancer previously treat 2-5 line anthracyclines , taxanes , capecitabine ( EMBRACE study ) . - The frequently report eribulin-related AEs asthenia/fatigue ( 65 % ) , alopecia ( 60 % ) , neutropenia ( 60 % ) , nausea ( 44 % ) , anemia ( 28 % ) , pyrexia ( 23 % ) , leucopenia ( 22 % ) , anorexia ( 21 % ) , constipation ( 19 % ) , vomit ( 18 % ) , peripheral neuropathy ( 5.5 % ; grade 3 ) . Grade 4 neutropenia occur 32 % patient , febrile neutropenia occur 5.5 % patient . The frequency grade 3/4 AEs less 3 % . This toxicity profile overlap lapatinib . - There uncertainty far every 3 week schedule eribulin mesylate dose 2.0 mg/m² would well tolerate . Several phase II study currently conduct various non-breast cancer indication compare d1+8 q d21 d1 q d21 schedule . - The aim randomize phase II study compare efficacy tolerability two dose-schedules eribulin plus lapatinib HER2-positive breast cancer , pre-treated trastuzumab adjuvant and/or metastatic setting .</brief_summary>
	<brief_title>Efficacy Tolerability Eribulin Plus Lapatinib Patients With Metastatic Breast Cancer ( E-VITA )</brief_title>
	<detailed_description>Primary Objectives 1 . To assess time progression ( TTP ) eribulin dose 1.23 mg/m² IV day 1+8 , q 21 eribulin give dose 1.76 mg/m² IV day 1 , q d21 combination lapatinib . 2 . To assess safety toxicity treatment arm . Secondary Objectives 1 . To determine objective response rate treatment arm . 2 . To determine overall clinical benefit rate ( CR + PR + SD &gt; 24 week ) treatment arm . 3 . To determine overall survival treatment arm 3 year 1st patient randomize . 4 . To assess biomarkers like PI3K mutation , PTEN expression , c-myc primary tumor correlate TTP treatment arm .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Written inform consent prior begin specific protocol procedure , include expect cooperation patient treatment followup , must obtain document accord local regulatory requirement . Complete baseline documentation must submit via webbased data collection system MedCODES® GBG Forschungs GmbH . Histological confirm carcinoma breast overexpression HER2 ( IHC3+ FISH pos. , accord current guideline AGO ) . Every effort make make paraffin embed tissue slide original tumor and/or metastatic tissue available confirmation diagnosis additional translational research . Locally advance metastatic stage disease suitable surgery radiotherapy alone . Patients must either measurable nonmeasurable target lesion accord RECIST criterion . Complete stag workup within 4 week prior registration . All patient must chest Xray ( PA lateral ) , abdominal ultrasound CT scan MRI , bone scan . In case positive bone scan , bone Xray mandatory . Other test may perform clinically indicate . The follow previous systemic treatment eligible : Previous treatment trastuzumab either ( neo ) adjuvant treatment early breast cancer and/or first and/or second line treatment metastatic breast cancer , adjuvant 2 chemotherapy regimen metastatic breast cancer , previous chemotherapy regimen anthracycline base , maximum cumulative dose prior anthracycline therapy must exceed 360 mg/m² doxorubicin 720 mg/m² epirubicin , adjuvant endocrine therapy , palliative endocrine treatment , treatment bisphosphonates ( adjuvant and/or palliative ) , least 4 week since radiotherapy , full recovery . The measurable disease must completely outside radiation field must pathologic proof progressive disease . 7 . Age &gt; 18 year . 8 . ECOG performance status 02 . 9 . Laboratory requirement : Absolute neutrophil count ≥ 1500 cells/ul , hemoglobin ≥ 10.0 g/dL ( hemoglobin &lt; 10.0 g/dL acceptable correct growth factor transfusion ) , platelet count ≥100,000 cells/ul , bilirubin &lt; = 1.5x upper limit normal institution ( ULN ) , elevation transaminase alkaline phosphatase &lt; 2.5x ULN &lt; 5x ULN patient liver metastasis , creatinine &lt; = 1.5 x ULN creatinineclearance &gt; 40 ml/min ( accord Cockroft Gault ) , negative pregnancy test ( urine serum ) within 14 day prior registration woman childbearing potential . 10 . Normal cardiac ejection function determine cardiac ultrasound ( LVEF institutional normal range ) . 11 . A female either : Nonchildbearing potential i.e. , physiologically incapable become pregnant history hysterectomy , bilateral oophorectomy ( ovarectomy ) , bilateral tubal ligation postmenopausal status . Childbearing potential negative serum pregnancy test within 2 week prior registration , preferably close first dose possible , agree use adequate contraception . Acceptable contraceptive method , use consistently accordance product label instruction physician , follow : An intrauterine device document failure rate le 1 % per year . Vasectomized partner sterile prior female subject 's entry sole sexual partner female . Complete abstinence sexual intercourse 14 day exposure investigational product , dose period , least 21 day last dose investigational product . Doublebarrier contraception ( condom spermicidal jelly , foam suppository , film ; diaphragm spermicide ; male condom diaphragm spermicide ) . 12 . Female patient lactate discontinue nursing prior first dose study drug refrain nursing throughout treatment period 14 day follow last dose study drug . 13 . Patients must available compliant treatment followup . Patients register trial must treat follow participate cooperate center . Known hypersensitivity reaction compound incorporated substance ( e.g . halichondrin B and/or halichondrin B chemical derivative ) . Patients receive eribulin lapatinib . Concurrent immunotherapy hormonal therapy ( antihormonal , contraceptive and/or replacement therapy ) . Bisphosphonates may continue . Life expectancy le 3 month . Parenchymal brain metastasis , unless adequately treat neurosurgery , radiotherapy , radiosurgery combination . Any ongoing toxicity prior anticancer therapy grade &gt; 1 and/or progress severity , except alopecia stable sensory neuropathy Grade 2 . Known suspected congestive heart failure ( &gt; NYHA I ) and/or coronary heart disease , angina pectoris require antianginal medication , previous history myocardial infarction , evidence transmural infarction ECG , un poorly control arterial hypertension ( i.e . BP &gt; 150/100 mmHg treatment two antihypertensive drug ) , rhythm abnormality require permanent treatment , clinically significant valvular heart disease . Currently active infection . History malignancy within last 5 year could affect diagnosis , assessment prognosis metastatic breast cancer . Malabsorption syndrome insufficient gastrointestinal function , preexist diagnosis ulcerative colitis . Concurrent treatment experimental drug ; participation another clinical trial investigational market drug within 30 day prior study entry . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>German Breast Group</keyword>
	<keyword>GBG Forschungs GmbH</keyword>
	<keyword>GBG</keyword>
	<keyword>GBG 64</keyword>
	<keyword>E-VITA</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Eribulin</keyword>
	<keyword>Lapatinib</keyword>
	<keyword>Halaven</keyword>
	<keyword>Tyverb</keyword>
</DOC>